Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company engaged in discovering, developing and commercializing therapies for neurological and psychiatric disorders. Its pipeline is led by azetukalner, an investigational Kv7 potassium channel opener in Phase 3 studies for focal… From the company’s description.
In fiscal 2025, Xenon Pharmaceuticals Inc. reported revenue of $7.50M and a net loss of $345.91M. Its operating margin was −4974.3%, and operations used $279.12M in cash. Over the twelve months to Jun 30, 2026, revenue was $0.00M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Xenon Pharmaceuticals Inc. does
In the company’s own words
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company engaged in discovering, developing and commercializing therapies for neurological and psychiatric disorders. Its pipeline is led by azetukalner, an investigational Kv7 potassium channel opener in Phase 3 studies for focal onset and primary generalized tonic-clonic seizures, major depressive disorder and bipolar depression. The company’s early-stage programs include Kv7 potassium channel openers and Nav sodium channel modulators for pain, as well as a Nav1.1 program for Dravet syndrome. In 2025, it initiated Phase 1 studies of XEN1701, a Nav1.7 candidate, and XEN1120, a Kv7 candidate, for pain. Xenon also partners with Neurocrine Biosciences on sodium channel inhibitor programs for epilepsy; Neurocrine’s NBI-921355 entered Phase 1 in 2025. The company’s strategy includes advancing proprietary candidates and selectively collaborating to develop or commercialize products. Its development portfolio spans multiple Phase 3 programs, with azetukalner as its most advanced candidate.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BURNABY
- Fiscal year end
- December
- CIK
- 1582313
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Xenon Pharmaceuticals Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Xenon Pharmaceuticals Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Xenon Pharmaceuticals Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Xenon Pharmaceuticals Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Xenon Pharmaceuticals Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Xenon Pharmaceuticals Inc.'s last four quarterly filings that the numbers alone won't show?”